Cambridge Respiratory Innovations was founded in 2013 with the aim of transforming respiratory care. Our patent-protected technology brings the world's first ultra-high sensitivity hand-held fully-connected capnometer to the front lines of healthcare. With our proprietary data analytics software platform and artificial intelligence solutions, we provide actionable insights at the point of care.
Thanks to our CE-marked, proprietary, CO2 sensing technologies, we are able to collect more data from normal breathing than ever before, providing new insights into lung function. Our fully connected hand-held device is simple to use, requires little-to-no training and is perfect for use within the clinic or at home. The device is suitable for patients as young as 4 years old as well as the elderly. With unique insights, as well as correlations to FEV1, PEF and FEV25-75, the N-Tidal brings a new paradigm in the diagnosis, monitoring and management of cardiorespiratory conditions.
We are supporting several clinical research projects and international clinical trials, scheduled to go live in Q2 2020. Our services provide simple and accurate methods to:
Our mission is to bring specialist cardiorespiratory care into the generalist setting and home. Thanks to our proprietary software platform, we aim to support care teams and their patients through actionable insights, for example:
